GG00BMFG5F62 - Common Stock
1.88 -0.04 (-2.08%)
After market: 1.82 -0.06 (-3.19%)
OKYO PHARMA LTD
NASDAQ:OKYO (9/26/2023, 7:24:41 PM)After market: 1.82 -0.06 (-3.19%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The firm operates through the research and development of biotechnological and pharmaceutical products segment. The Company’s technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Company’s wholly owned subsidiary is OKYO Pharma US Inc.
OKYO PHARMA LTD
55 Park Lane
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused...
An ophthalmology-focused bio-pharmaceutical company OKYO Pharma (NASDAQ:OKYO) withdraws its proposed public offering of ordinary shares and its termination of Freedom Capital Markets as...
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused...
Here you can normally see the latest stock twits on OKYO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.